- Home
- BMEA vs NCSM Comparison
BMEA vs NCSM Comparison
Compare BMEA & NCSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- NCSM
- Stock Information
- Founded
- BMEA 2017
- NCSM 2006
- Country
- BMEA United States
- NCSM United States
- Employees
- BMEA N/A
- NCSM N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- NCSM Oilfield Services/Equipment
- Sector
- BMEA Health Care
- NCSM Energy
- Exchange
- BMEA Nasdaq
- NCSM Nasdaq
- Market Cap
- BMEA 65.8M
- NCSM 61.1M
- IPO Year
- BMEA 2021
- NCSM 2017
- Fundamental
- Price
- BMEA $1.67
- NCSM $32.01
- Analyst Decision
- BMEA Strong Buy
- NCSM
- Analyst Count
- BMEA 11
- NCSM 0
- Target Price
- BMEA $27.60
- NCSM N/A
- AVG Volume (30 Days)
- BMEA 713.5K
- NCSM 9.5K
- Earning Date
- BMEA 05-05-2025
- NCSM 04-30-2025
- Dividend Yield
- BMEA N/A
- NCSM N/A
- EPS Growth
- BMEA N/A
- NCSM N/A
- EPS
- BMEA N/A
- NCSM 3.27
- Revenue
- BMEA N/A
- NCSM $168,704,000.00
- Revenue This Year
- BMEA N/A
- NCSM $7.03
- Revenue Next Year
- BMEA N/A
- NCSM $5.82
- P/E Ratio
- BMEA N/A
- NCSM $9.52
- Revenue Growth
- BMEA N/A
- NCSM 18.16
- 52 Week Low
- BMEA $1.53
- NCSM $15.90
- 52 Week High
- BMEA $13.43
- NCSM $38.95
- Technical
- Relative Strength Index (RSI)
- BMEA 41.85
- NCSM 53.62
- Support Level
- BMEA $1.61
- NCSM $29.15
- Resistance Level
- BMEA $2.30
- NCSM $32.71
- Average True Range (ATR)
- BMEA 0.20
- NCSM 1.76
- MACD
- BMEA -0.00
- NCSM 0.29
- Stochastic Oscillator
- BMEA 21.74
- NCSM 45.36
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About NCSM NCS Multistage Holdings Inc.
NCS Multistage Holdings Inc provides products and support services that facilitate the optimization of oil and natural gas well completions and field development strategies. NCS provides its products and services to exploration and production companies for use in onshore wells, predominantly wells that have been drilled with horizontal laterals in unconventional oil and natural gas formations. The company's primary offering is its fracturing systems products and services, which enable efficient pinpoint stimulation: the process of individually stimulating each entry point into a formation targeted by an oil or natural gas well. Geographically, majority of revenue is generated from United States.